Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
GlobalData on MSN4d
Curevo procures $110m and former-GSK exec for shingles vaccine candidate
Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein. The ...
Fierce Biotech4d
Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
STAT5d
Small vaccine maker names Operation Warp Speed leader as chairman, raises $110 million
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
GeekWire5d
Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo is taking on biotech giant GlaxoSmithKline, which sells Shingrix, its shingles vaccine approved in 2017. Medicxi, a European biotech-focused firm, led the Series B round. Other backers ...
Morningstar5d
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Former Chair of GSK’s vaccine business and Chief Scientific ... B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European ...
manilatimes5d
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Former Chair of GSK's vaccine business and Chief Scientific Advisor ... of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new ...